Most Read Articles

Annual influenza vaccination is recommended for all persons ≥6 months old without a contraindication. Influenza vaccines available this season in the US are listed in Table 3.

The injectable GIP/GLP-1 receptor agonist tirzepatide (Mounjaro – Lilly), which was approved by the FDA in 2022 for treatment of type 2 diabetes, has now been approved to reduce the risk of MACE in adults with type 2 diabetes who are at high risk for these events. Tirzepatide is also available as Zepbound for chronic weight management and for treatment of obstructive sleep apnea in adults with obesity.

View the Comparison Table: Some Drugs for Migraine Prevention

Initial treatment of allergic rhinitis (AR) depends on the severity of symptoms and whether they are intermittent or persistent (see Table 1).

Insulin icodec (Awiqli – Novo Nordisk), an ultra-long-acting basal human insulin analog, has been approved by the FDA for once weekly treatment of type 2 diabetes. Two once-daily, long-acting insulin analogs are available in the US: glargine U300 (Toujeo) and degludec U100 and U200 (Tresiba). Insulin icodec has been available in Canada since 2024.

Indications for preventive treatment of migraine include frequent or severe attacks, contraindications to or toxicity with acute treatments, and patient preference. Drugs for acute treatment of migraine were reviewed in a previous issue.

The FDA has approved daraxonrasib (Rasonque – Revolution Medicines), an oral RAS GTPase multi-selective inhibitor, for treatment of metastatic pancreatic adenocarcinoma, regardless of RAS G12 mutation status, in adults who received at least one prior systemic therapy or are not candidates for multi-agent systemic therapy. It is the first RAS GTPase inhibitor to be approved in the US for any indication.

The FDA has approved Leqembi Iqlik, the subcutaneous (SC) formulation of the amyloid beta-directed monoclonal antibody lecanemab, for once-weekly initiation dosing in patients with Alzheimer's disease (AD). The SC formulation was previously approved only for maintenance treatment in patients who had received IV lecanemab for at least 18 months.

View the Comparison Table: Triptans

View the Comparison Table: Amyloid Beta-Directed Antibodies for Alzheimer's Disease